SCHEMBL2117356

SCHEMBL2117356

CN(C)c1ccccc1S(N)(=O)=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 10/20 0.67
HTR6 P50406 1/20 0.60
CA1 P00915 8/20 0.50
CA9 Q16790 8/20 0.50
CA12 O43570 4/20 0.50
CA4 P22748 3/20 0.50
CA6 P23280 3/20 0.50
CA5A P35218 3/20 0.50
CA7 P43166 2/20 0.50
CA5B Q9Y2D0 2/20 0.50
CYP2C9 P11712 1/20 0.50
CA14 Q9ULX7 1/20 0.50
F2 P00734 3/20 0.44
PRSS1 P07477 3/20 0.44
PRSS2 P07478 3/20 0.44
PRSS3 P35030 3/20 0.44
TDP1 Q9NUW8 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29469920 1.00 CA2 (0.67) CA2HTR6CA1CA9CA12
SCHEMBL10891110 0.82 CA2 (0.51) CA2HTR6CA1CA9CA12
SCHEMBL8149846 0.80 CA2 (0.64) CA2HTR6CA1CA9CA12
SCHEMBL108421 0.80 CA2 (1.00) CA2CA1CA9F2PRSS1
SCHEMBL28584350 0.80 CA2 (0.54) CA2HTR6CA1CA9CA12
SCHEMBL3971963 0.79 HTR6 (0.56) CA2HTR6CA1CA9CA12
SCHEMBL11407481 0.79 CA2 (0.96) CA2CA1CA9F2PRSS1
SCHEMBL7633146 0.79 CA2 (0.49) CA2HTR6CA1CA9CA12
SCHEMBL29581330 0.79 CA2 (0.49) CA2HTR6CA1CA9CA12
SCHEMBL6265807 0.78 HTR6 (0.60) CA2HTR6CA1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056829-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER Exelixis, Inc. (US) 2009-05-13 EP claimed
WO-2008021389-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS, INC. (US) 2008-02-21 WO claimed
EP-0794952-B1 POLYMERISABLE AROMATIC CARBOXYLIC ACID AND CARBOXYLIC ACID ANHYDRIDES WITH CYCLIC CARBONATE GROUPS AND COMPOSITIONS THAT CONTAIN THESE COMPOUNDS HERAEUS KULZER GMBH & CO KG (DE) 2000-02-23 EP claimed
EP-3765447-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS Kezar Life Sciences (US) 2021-01-20 EP disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
US-20100204187-A1 Purine Derivatives PALAU PHARMA, S.A. (ES) 2010-08-12 US disclosed
EP-2056829-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER Exelixis, Inc. (US) 2009-05-13 EP disclosed
US-20080286377-A1 ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2008-11-20 US disclosed
WO-2008021389-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS, INC. (US) 2008-02-21 WO disclosed
EP-1444972-B1 Hardenable dental material HERAEUS KULZER GMBH (DE) 2006-03-29 EP disclosed
EP-0776650-A2 Dental adhesive Heraeus Kulzer GmbH (DE) 1997-06-04 EP disclosed
WO-1997003063-A1 POLYMERISABLE AROMATIC CARBOXYLIC ACID AND CARBOXYLIC ACID ANHYDRIDES WITH CYCLIC CARBONATE GROUPS AND COMPOSITIONS THAT CONTAIN THESE COMPOUNDS HERAEUS KULZER GMBH (DE) 1997-01-30 WO disclosed
EP-0497157-B1 Crosslinked molded dental articles HERAEUS KULZER GMBH (DE) 1996-10-16 EP disclosed
EP-0471252-B1 N-alkyl-N-(meth)acryloyloxyalkylcarboxamides of aromatic carboxylic acids and of aromatic carboxylic anhydrides and adhesives containing these compounds BAYER AG (DE) 1994-03-30 EP disclosed
US-5294646-A N-alkyl-n-(meth)acryloyloxyalkylcarboxamides of aromatic carboxylic acids and aromatic carboxylic acid anhydrides, and adhesives containing these compounds BAYER AKTIENGESELLSCHAFT (DE) 1994-03-15 US disclosed
US-5270350-A Polyfunctional (meth)acrylic acid ester BAYER AKTIENGESELLSCHAFT (DE) 1993-12-14 US disclosed
US-5241081-A N-ALKYL-N-(METH)ACRYLOYLOXYALKYLCARBOXAMIDES OF AROMATIC CARBOXYLIC ACIDS AND AROMATIC CARBOXYLIC ACID ANHYDRIDES, AND ADHESIVES CONTAINING THESE COMPOUNDS BAYER AKTIENGESELLSCHAFT (DE) 1993-08-31 US disclosed
EP-0497157-A2 Crosslinked molded dental articles Heraeus Kulzer GmbH & Co.KG (DE) 1992-08-05 EP disclosed
EP-0471252-A1 N-alkyl-N-(meth)acryloyloxyalkylcarboxamides of aromatic carboxylic acids and of aromatic carboxylic anhydrides and adhesives containing these compounds BAYER AG (DE) 1992-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204187-A1 Purine Derivatives JAK3, JAK1, JAK2 CA2 4678/4885HTR6 1889/4885CA1 4720/4885
US-20080286377-A1 ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS SOST, BMP6, BMP2 CA2 2655/4885HTR6 3965/4885CA1 1814/4885
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 CA2 291/4885HTR6 3946/4885CA1 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.